Skip to main content
SpringerLink
Log in

Therapie des ALK-positiven nichtkleinzelligen Lungenkarzinoms

ALK-Inhibitoren im Head-to-Head-Vergleich

  • journal club
  • Published:
InFo Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Lockney NA, Wu AJ. J Thorac Dis. 2017;9(2):E152–4.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Peters S et al. N Engl J Med. 2017;377(9):829–38.

    Article  CAS  PubMed  Google Scholar 

  3. Costa DB. Lancet Oncol. 2017;18(7):837–9.

    Article  PubMed  Google Scholar 

  4. Shaw AT et al. Lancet Oncol. 2017;18(7):874–86.

    Article  CAS  PubMed  Google Scholar 

Originalie

  • Peters S et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):829–38.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. München, Deutschland

    Andreas Schalhorn (Onkologische Schwerpunktpraxis)

Authors
  1. Andreas Schalhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Schalhorn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schalhorn, A. ALK-Inhibitoren im Head-to-Head-Vergleich. Info Onkol. 20, 28–30 (2017). https://doi.org/10.1007/s15004-017-5848-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-017-5848-8

Schlüsselwörter

Search

Navigation